Article

Adjuvant personalized cancer vaccine: is this the end of metastatic kidney cancer

Nature Reviews Urology
DOI: 10.1038/s41585-025-01018-6
0Citations
Citations of this article
1Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The first study of personalized cancer vaccines for renal cell carcinoma with breakthrough results in the adjuvant setting has been published, showing a 100% efficacy rate and negligible toxic effects. However, important questions remain concerning long-term effectiveness.

Cite

CITATION STYLE

APA

Schmidinger, M., & Huebner-Resch, I. (2025, September 1). Adjuvant personalized cancer vaccine: is this the end of metastatic kidney cancer. Nature Reviews Urology. Nature Research. https://doi.org/10.1038/s41585-025-01018-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free